Fig. 3

Influence of PRAS40 on the cell viability activated by mTOR. Immunoblotting (A, C, E) or cell viability assay (B, D, F). Tsc2^+/+ or Tsc2^−/− MEFs transfected with control shRNA or PRAS40 shRNA (A, B). Tsc2^−/− MEFs were transfected with control shRNA, mTOR shRNA2, or mTOR shRNA2 together with empty vector or PRAS40 expression vector (C, D). Tsc2^−/− MEFs transfected with control shRNA or PRAS40 shRNA were treated with or without rapamycin (rapa, 5 nM) (E, F). The quantification values of the band density were labeled above the bands. Bars, SD. *P < 0.05, **P < 0.01, ***P < 0.001 from one-way ANOVA